Home › Trials › NCT07415954

Different doses of NNC0662-0419 versus semaglutide and placebo to lower blood sugar in adults with type 2 diabetes

Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

Phase 2 Interventional Novo Nordisk A/S · NCT07415954

This trial will test whether different doses of the experimental medicine NNC0662-0419 lower blood sugar in adults with type 2 diabetes compared with placebo or semaglutide.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment270 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorNovo Nordisk A/S Industry-sponsored
Locations63 sites (Lancaster, California and 62 other locations)
Trial IDNCT07415954 on ClinicalTrials.gov

What this trial studies

This Phase 2, randomized trial gives participants either NNC0662-0419 at varying doses, semaglutide, or placebo, with assignment decided by chance. The study measures blood sugar control (HbA1c) and safety outcomes over the treatment period. NNC0662-0419 is a new medicine that has been previously tested in humans but is not yet approved, while semaglutide is an approved diabetes medication used here as an active comparator. The goal is to identify effective and tolerable dosing for NNC0662-0419 in adults with type 2 diabetes.

Who should consider this trial

Good fit: Adults aged 18–75 with type 2 diabetes and an HbA1c of 7.0–10.0% who are willing to pursue substantial weight loss (>25% of baseline weight) and meet other eligibility criteria may qualify.

Not a fit: People with uncontrolled or unstable diabetic retinopathy/maculopathy, known hypoglycaemic unawareness, recent treatment with other diabetes or obesity medications, or who cannot meet the weight-loss requirement are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, NNC0662-0419 could provide an additional option to lower blood sugar for people with type 2 diabetes, potentially with a different dosing or side-effect profile than current medicines.

How similar studies have performed: Approved drugs in the same class as semaglutide have reliably lowered blood sugar and body weight, but NNC0662-0419 is a novel compound with limited published efficacy data to date.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion criteria

* Male or female (sex at birth).
* Age 18-75 years (both inclusive) at the time of signing the informed consent.
* Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening.
* Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline).

Exclusion criteria

* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

Where this trial is running

Lancaster, California and 62 other locations

+13 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Diabetes Mellitus, Type 2
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.